Patents by Inventor Ian H. Pike

Ian H. Pike has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10815230
    Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: October 27, 2020
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Ian H. Pike, Karsten Kuhn, Stefan Kienle, William D. O. Hamilton, Jonathan R. Heal, Joseph M. Sheridan
  • Publication number: 20180186786
    Abstract: The present invention provides 2-Methyl-amino-3-[(4-fluorophenyl)carbonyl]indolizine-1-carboxamide of formula (I) or a pharmaceutically acceptable salt thereof; and its therapeutic uses in the treatment of neurodegenerative disorders, in particular tauopathies and most preferably in the treatment of Alzheimer's disease.
    Type: Application
    Filed: May 13, 2016
    Publication date: July 5, 2018
    Applicant: ELECTROPHORETICS LIMITED
    Inventors: Ian H. Pike, Karsten Kuhn, Stefan Kienle, William D.O. Hamilton, Jonathan R. Heal, Joseph M. Sheridan
  • Patent number: 9789111
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: October 17, 2017
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton, Ian H. Pike
  • Patent number: 9763947
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: September 19, 2017
    Assignee: ELECTROPHORETICS LIMITED
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D. O. Hamilton, Ian H. Pike
  • Publication number: 20160058745
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: September 1, 2015
    Publication date: March 3, 2016
    Applicant: Electrophoretics Limited
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian H. Pike
  • Publication number: 20150209368
    Abstract: The invention relates to pharmaceutical compositions having casein kinase 1 delta (CK1?) inhibitors and to the use of the inhibitors in the treatment of neurodegenerative disorders such as Alzheimer's disease.
    Type: Application
    Filed: April 2, 2015
    Publication date: July 30, 2015
    Applicant: Electrophoretics Limited
    Inventors: Joseph M. Sheridan, Jonathan R. Heal, William D.O. Hamilton, Ian H. Pike
  • Patent number: 7402315
    Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8023 to 8235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: July 22, 2008
    Assignees: Common Services Agency, Murex Diagnostics Limited
    Inventors: Peter Simmonds, Peng L. Yap, Ian H. Pike
  • Publication number: 20050032047
    Abstract: The present invention relates to a polynucleic acid composition comprising or consisting of at least one polynucleic acid containing 8 or more contiguous nucleotides corresponding to a nucleotide sequence from the region spanning positions 417 to 957 of the Core/E1 region of HCV type 3; and/or the region spanning positions 4664 to 4730 of the NS3 region of HCV type 3; and/or the region spanning positions 4892 to 5292 of the NS3/4 region of HCV type 3; and/or the region spanning positions 8 023 to 8 235 of the NS5 region of the BR36 subgroup of HCV type 3a; and/or the coding region of HCV type 4a starting at nucleotide 379 in the core region; and/or the coding region of HCV type 4; and/or the coding region of HCV type 5, with said nucleotide numbering being with respect to the numbering of HCV nucleic acids as shown in Table 1, and with said polynucleic acids containing at least one nucleotide difference with known HCV type 1, and/or HCV type 2 genomes in the above-indicated regions, or the complement thereof.
    Type: Application
    Filed: May 5, 1994
    Publication date: February 10, 2005
    Inventors: PETER SIMMONDS, PENG L. YAP, IAN H. PIKE